首页> 外文OA文献 >Modelling The Economic Impact of Implementing Treatment-Free Remission (TFR) In Philadelphia+ (PH+) Chronic Myelogenous Leukemia In Chronic Phase (CML-CP) Patients Treated In First Line (1l) With The Tyrosine Kinase Inhibitors (TKI): Imatinib And Nilotinib

【2h】

Modelling The Economic Impact of Implementing Treatment-Free Remission (TFR) In Philadelphia+ (PH+) Chronic Myelogenous Leukemia In Chronic Phase (CML-CP) Patients Treated In First Line (1l) With The Tyrosine Kinase Inhibitors (TKI): Imatinib And Nilotinib

机译：模拟在第一线（1L）治疗的慢性相（CML-CP）慢性髓性白血病中实施Phildelphia +（pH +）慢性髓性白血病的经济影响，用酪氨酸激酶抑制剂（TKI）：伊替尼和尼洛替尼（TKI）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
E Sauvage; J Duco; S Nizard; S Arroum; F Mahon; P Kuizenga; J Ricci;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. MODELLING THE ECONOMIC IMPACT OF IMPLEMENTING TREATMENT FREE REMISSION (TFR) IN PHILADELPHIA plus (PH plus ) CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE (CML-CP) PATIENTS TREATED IN FIRST LINE (1L) WITH THE TYROSINE KINASE INHIBITORS (TKI): IMATINIB AND NIL OTINIB [J] . Sauvage E., Duco J., Nizard S., Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2016,第7期

机译：模拟在第一线（1L）酪氨酸激酶抑制剂（TKI）治疗的慢性阶段（CML-CP）患者中，在费城加上（PH +）慢性粒细胞白血病中实施无治疗释放（TFR）的经济影响奥蒂尼
2. Treatment-Free Remission (TFR) Following Frontline Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): 192-Weeks Data from the ENESTfreedom Study [J] . Radich Jerald P., Ross David M., Masszi Tamas, Clinical lymphoma, myeloma & leukemia . 2019,第Suppla1期

机译：在慢性期慢性骨髓白血病患者的前线NILOTINIB（CML-CP）中的无治疗缓解（TFR）：来自Enestfreedom研究的192周数
3. ENESTop 192-Weeks Results: Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After Stopping Second-Line Nilotinib [J] . Mahon Francois-Xavier, Boquimpani Carla, Takahashi Naoto, Clinical lymphoma, myeloma & leukemia . 2019,第Suppla1期

机译：192周的结果：在停止第二线Nileotinib后慢性骨髓白血病患者的免疫缓解（TFR）慢性相（CML-CP）。
4. Combination effects of repetitive pulsed magnetic stimulation and tyrosine kinase inhibitor imatinib for chronic myeloid leukemia cell line TCC-S [C] . S. Yamaguchi, M. Sekino, Y. Sato, Intermag Conference . 2006

机译：重复脉冲磁刺激和酪氨酸激酶抑制剂慢性髓性白血病细胞系TCC-S的组合效应
5. Modeling Imatinib-Treated Chronic Myelogenous Leukemia and the Immune System [D] . Peters, Cara Disa. 2020

机译：拟模伊替尼治疗的慢性髓性白血病和免疫系统
6. Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance [O] . Elias Jabbour, Philipp D. le Coutre, Jorge Cortes, -1

机译：伊替尼耐药后尼洛替尼治疗慢性相的pH +慢性骨髓白血病患者的结果预测

Modelling The Economic Impact of Implementing Treatment-Free Remission (TFR) In Philadelphia+ (PH+) Chronic Myelogenous Leukemia In Chronic Phase (CML-CP) Patients Treated In First Line (1l) With The Tyrosine Kinase Inhibitors (TKI): Imatinib And Nilotinib

著录项

引文网络

相似文献

相关主题

期刊订阅